(SAN DIEGO – November 5, 2015) – St. Louis-based MediBeacon™ Inc., maker of a proprietary noninvasive real-time monitoring system for kidney function, today presented the results of initial human clinical trials at the American Society of Nephrology (ASN) Kidney Week meetings.
The American Society of Nephrology leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients. Kidney Week is the World's Premier Nephrology Meeting
The meeting draws appoximately13,000 kidney professionals from across the globe. Kidney Week provides participants exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
The poster entitled “Initial Clinical Trial Results of a Real-Time Point-of-Care Glomerular Filtration Rate Measurement Utilizing a Novel Fluorescent Tracer Agent” summarizes the results from the first in a series of clinical trials.
The poster is available for viewing or download here.
###
About MediBeacon Inc.
MediBeacon was co-founded in 2012 by Steven J. Hanley and Dr. Richard B. Dorshow to acquire the optical diagnostics and therapeutics program from Mallinckrodt. Mr. Hanley, former president of Covidien Mallinckrodt’s Imaging Solutions business unit, is MediBeacon’s CEO. Dr. Dorshow, who established and led development of the optical diagnostics and therapeutics program at Mallinckrodt, is MediBeacon’s chief scientific officer. The company holds numerous patents on its light-activated agents, which are the foundation of MediBeacon’s technology platform. Learn more about MediBeacon at zh-hk.medibeacon.com.
